Oxford Health researcher contributes to BMJ article on new treatments for depression

The article summarises research into new and emerging treatments to target major depressive disorder (MDD), including drugs such as psychedelics.

MDD has a substantial personal and socioeconomic impact and effective management of MDD is essential to improve the quality of life for people living with the condition.

Oxford Health NHS Foundation Trust offer support to people who have depression which has not responded to other treatments through the Interventional Psychiatry Service. Visit the website to learn more about our Ketamine Clinic, led by Dr Rupert McShane or contact them on email at: KetamineClinic@oxfordhealth.nhs.uk.